Halozyme Therapeutics, Inc. (HALO) Tops Q2 EPS by 2c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $110.19 -0.51%
Revenue Growth %: +36.2%
Financial Fact:
Interest and other income, net: 334K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +36.2%
Financial Fact:
Interest and other income, net: 334K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q2 EPS of ($0.13), $0.02 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $5.63 million.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Morgan Stanley Downgrades Sims Metal Management Ltd. (SGM:AU) (SMUPF) to Underweight
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
